Results 71 to 80 of about 2,404 (154)

Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025

Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged \u3c year) in the United States.
Orzel-Lockwood, Amber O., Schuster, Jennifer E., al, et, Zerr, Danielle M., Gertz, Shira J., Irby, Katherine, Payne, Amanda B., Calixte, Jemima M., Chiotos, Kathleen, Crandall, Hillary, Nofziger, Ryan A., Hume, Janet R., Simeone, Regina M., Kamidani, Satoshi, Shein, Steven L., Halasa, Natasha B., Maddux, Aline B., Michelson, Kelly N., Newhams, Margaret M., Bhumbra, Samina S., Chauhan, Jigar C., Guzman-Cottrill, Judith A., Coates, Bria M., Staat, Mary Allen, Kong, Michele, Martin, Lora M., Bradford, Tamara T., Cameron, Melissa A., Zambrano, Laura D.   +28 more
core   +1 more source

Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea

Human Vaccines & Immunotherapeutics
The current standard-of-care prophylaxis for respiratory syncytial virus (RSV) is primarily administered to high-risk infant populations. We conducted a cost-effectiveness analysis to determine the economically justifiable price of nirsevimab compared ...
Hyun Jin Han, Semin Jang, Ryu Dahye, Haeseon Lee, Jiyeon Lee, Eun Jin Bae, Samira Soudani, Hae Sun Suh   +7 more
doaj   +1 more source

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study

Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants. In 2024, the monoclonal antibody nirsevimab became available in Italy for all newborns during their first RSV season. Aims: The
Bonci, Enea, Petrarca, Laura, Spatuzzo, Mattia, Nenna, Raffaella, La Regina, Domenico Paolo, Antonelli, Guido, Midulla, Fabio, Pierangeli, Alessandra, Conti, Maria Giulia, Mancino, Enrica   +9 more
core   +1 more source

Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025)

Viruses
Nirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the
Paolo Manzoni, Matteo Riccò, Chryssoula Tzialla, Graziano Barera, Paolo Del Barba, Simona De Franco, Guido Pellegrini, Enrico Crapanzano, Giangiacomo Nicolini, Andrea Alba, Stefano Fiocchi, Mauro Vivalda, Giulia Natta, Alessandra Casati, Mariano Manzionna, Simone Rugolotto, Laura Saggioro, Simona Pesce, Maria Scavone, Antonietta Distilo, Vincenza Roseto, Antonino Di Toro, Luca Pierri, Gianfranco Scarpelli, Elvira Bonanno, Lidia Decembrino, Enrico Felici, Camilla Selvatico, Valentina Saracco, Francesco Morrone, Claudio Costantino, Cecilia Nobili, Mario Giuffrè   +32 more
doaj   +1 more source

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months

Children
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) in infants and young children, with significant morbidity, hospitalizations, and healthcare costs.
Andreea Văduva, Alexandru Dinulescu, Anca Cristina Drăgănescu, Sorin Claudiu Man, Doina Anca Pleșca   +4 more
doaj   +1 more source

Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.Research design and methods A cohort model was ...
Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W. Law, Diana Mendes   +9 more
doaj   +1 more source

Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis

Pediatric Reports
Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy ...
Brody J. Lipsett, Benjamin N. Fogel, Katherine E. Shedlock, Ian M. Paul, Eric W. Schaefer, Ruth E. Gardner, Leah D. Kaye, Steven D. Hicks   +7 more
doaj   +1 more source

Uneven Implementation of Nirsevimab Prophylaxis Resulted in Non-Uniform Reductions in RSV-Related Hospitalizations in Italy

Background/Objectives: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants. In the 2024–2025 season, passive newborn immunization with nirsevimab, a long-acting anti-RSV monoclonal antibody, was ...
Enrico Valletta, Anthea Mariani, Claudio Cafagno, Désirée Caselli, Francesco Accomando, Claudia Rossini, Martina Fornaro, Giulia Marozzi, Melodie O. Aricò, Daniela Trotta, Letizia Lorusso, Maurizio Aricò   +11 more
core   +1 more source

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant. To
De Mari, Pauline, Perceval, Lise Martin, Launay, Elise, Ouldali, Naim, Basmaci, Romain, Perceval, Lise, Martin, Aupiais, Camille, Rybak, Alexis, Cohen, Laure, de Pontual, Loic, Cohen, Robert, Lenglart, Lea, Levy, Corinne, Levieux, Karine, Béchet, Stéphane, Kramer, Rolf   +15 more
core   +1 more source